Roche-Backed Freenome Continues Industry’s Private Funding Rally with $254M Raise

Feb 15, 2024•over 1 year ago

Amount Raised

$254 Million

Round Type

series a

San FranciscoBiotechnology

Investors

American Cancer Society’s Bright Edge VenturesArk InvestmentsCormorant CapitalBain Capital Life SciencesRoche

Description

Freenome announced a $254 million private financing round, led by Roche, to support the development of its multiomics-based early detection tests for cancer.

Company Information

Company

Freenome

Location

San Francisco, California, United States

About

Freenome is breaking barriers to early cancer detection with a suite of blood tests built on its multiomics platform. The company recognizes that no single technology can identify every cancer due to the disease's inherent heterogeneity. Freenome's multimodal approach combines molecular biology and assays with computational biology, machine learning and multiple data types to tune into cancer's subtlest cues, even at the earliest stages of the disease.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech